Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

被引：1
|
作者：
Yuichi Terawaki
Chikayo Iwaya
Takashi Nomiyama
Dai Shimono
Tsuyoshi Horikawa
Yuki Fujimura-Tanaka
Toru Shigeoka
Nobuya Hamanoue
Ryoko Motonaga
Makito Tanabe
Toshihiko Yanase
Daiji Kawanami
机构：
[1] Fukuoka University,Department of Endocrinology and Diabetes Mellitus, School of Medicine
[2] Futata Tetsuhiro Clinic,undefined
[3] Muta Hospital,undefined
[4] Research Institute for Islet Biology,undefined
[5] Fukuoka University,undefined
来源：
Diabetology International | 2020年 / 11卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Insulin secretagogue; Glucose oscillation; Hypoglycemia; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：274 / 282
页数：8
相关论文
共 50 条
  • [31] The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus
    Garcia-Soria, G.
    Gonzalez-Galvez, G.
    Argoud, G. M.
    Gerstman, M.
    Littlejohn, T. W., III
    Schwartz, S. L.
    O'Farrell, A. -M.
    Li, X.
    Cherrington, J. M.
    Bennett, C.
    Guler, H. -P.
    DIABETES OBESITY & METABOLISM, 2008, 10 (04): : 293 - 300
  • [32] Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study
    Son, Cheol
    Makino, Hisashi
    Kasahara, Masato
    Tanaka, Tomohiro
    Nishimura, Kunihiro
    Taneda, S.
    Nishimura, Takeshi
    Kasama, Shu
    Ogawa, Yoshihiro
    Miyamoto, Yoshihiro
    Hosoda, Kiminori
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 180
  • [33] Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
    Kawasaki, Eiji
    Nakano, Yuko
    Fukuyama, Takahiro
    Uchida, Aira
    Sagara, Yoko
    Tamai, Hidekazu
    Tojikubo, Masayuki
    Hiromatsu, Yuji
    Koga, Nobuhiko
    WORLD JOURNAL OF DIABETES, 2021, 12 (12) : 2087 - 2095
  • [34] COMPARE THE EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN TYPE 2 DIABETES MELLITUS PATIENTS
    Konuru, Venkateswarlu
    Reddy, T. Rama Mohan
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018, 9 (11): : 4963 - 4967
  • [35] Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
    Nedosugova, L. V.
    Petunina, N. A.
    Galstyan, K. O.
    DIABETES MELLITUS, 2014, 17 (04): : 81 - 86
  • [36] Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
    Cox, Mary Elizabeth
    Rowell, Jennifer
    Corsino, Leonor
    Green, Jennifer B.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2010, 2 : 7 - 19
  • [37] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
    Deacon, Carolyn F.
    Holst, Jens J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2047 - 2058
  • [38] The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
    Robert Frederich
    Robert McNeill
    Niklas Berglind
    Douglas Fleming
    Roland Chen
    Diabetology & Metabolic Syndrome, 4
  • [39] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes
    Rosenstock, J.
    Lewin, A. J.
    Norwood, P.
    Somayaji, V.
    Nguyen, T. T.
    Teeter, J. G.
    Johnson, S. L.
    Dai, H.
    Terra, S. G.
    DIABETIC MEDICINE, 2011, 28 (04) : 464 - 469
  • [40] Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis
    Wu, D.
    Li, L.
    Liu, C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (01): : 30 - 37
12345